A Study of TRK-170 for the Treatment of Crohn's Disease
NCT ID: NCT01345799
Last Updated: 2014-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
123 participants
INTERVENTIONAL
2011-04-30
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To evaluate the efficacy of TRK-170
* To evaluate the PK characteristics of TRK-170
* To assess the safety of TRK-170
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease
NCT02378688
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
NCT01277666
Treg Immunotherapy in Crohn's Disease
NCT03185000
Efficacy and Safety of TD-1473 in Crohn's Disease
NCT03635112
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
NCT01316939
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TRK-170 Low Dose
TRK-170
TRK-170 Middle Dose
TRK-170
TRK-170 High Dose
TRK-170
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TRK-170
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has stable disease activity
Exclusion Criteria
* Patient with clinically significant deviations in laboratory values
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Toray Industries, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Belgium
Belgium, , Belgium
Bulgaria
Bulgaria, , Bulgaria
Czech Republic
Czech Republic, , Czechia
France
France, , France
Hungary
Hungary, , Hungary
Latvia
Latvia, , Latvia
The Netherlands
The Netherlands, , Netherlands
Norway
Norway, , Norway
Poland
Poland, , Poland
Romania
Romania, , Romania
Serbia
Serbica, , Serbia
Sweden
Sweden, , Sweden
Ukraine
Ukraine, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
170CDT01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.